Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053898 · ClinicalTrials.gov registry record · Phase 3
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,104
- Enrollment target
NCT00053898: Completed Phase 3 study, sponsored by NSABP Foundation.
NCT00053898 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 3,104 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (302% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053898, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,104 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production. It is not yet known whether anastrozole is more effective than tamoxifen in preventing the recurrence of breast cancer. PURPOSE: This randomized phase III trial is studying anastrozole to see how well it works compared to tamoxifen in preventing the recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ who are undergoing lumpectomy and radiation therapy.
Primary Outcome
Percentage of patients free from breast cancer event at 10 years where events include local, regional, or distant recurrence or contralateral breast cancer, invasive or DCIS.
Interventions
- RADIATION Radiation Therapy
- DRUG anastrozole
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,104 participants |
| Start Date | 2003-01 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
What the finished NCT00053898 record still lists
NCT00053898 is an interventional study that assigns participants to a tested intervention. Its 3,104 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (302% higher).
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT00053898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00053898 about?
NCT00053898 is a clinical study titled "Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production. It is not yet known whether anastrozole is more effective than tamoxifen in preventing the re...
What is the current status of trial NCT00053898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,104 participants. The study started on 2003-01. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00053898?
The interventions under investigation include: Radiation Therapy (RADIATION), anastrozole (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00053898?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00053898's enrollment target sits among peer trials
3,104 76th of 2000 higher than 1,925 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia